Evaluation of prognostic factors for advanced ovarian cancer treatment with an emphasis on optimal primary cytoreduction

被引:0
作者
Vrhkar, Natasa [1 ]
Vakselj, Ales [1 ]
Verdenik, Ivan [1 ]
Smrkolj, Spela [1 ]
Barbic, Matija [1 ]
Cvjeticanin, Branko [1 ]
Meglic, Leon [1 ]
Kobal, Borut [1 ]
机构
[1] Univ Klin Ctr Ljubljana, Ginekol Klin, Klin Oddelek Ginekol, Ljubljana 1000, Slovenia
来源
ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL | 2012年 / 81卷 / 7-8期
关键词
ovarian cancer; prognostic factors; cytoreduction; residual tumour; GYNECOLOGIC-ONCOLOGY-GROUP; SURVIVAL; SURGERY; CARCINOMA; IMPACT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Initial surgical debulking followed by a systemic chemotherapy is the standard treatment sequence for advanced ovarian cancer (AOC) treatment. The purpose of this article is to evaluate prognostic factors that impact the success of AOC treatment. Methods: All patients with AOC (FIGO stage III and IV) who were surgically treated at the Division of Gynaecology, University Medical Centre of Ljubljana, in the period from 2003 to 2008 and further received cytotoxic chemotherapy at the Institute of Oncology in Ljubljana were included in this retrospective study. Women with advanced borderline ovarian cancer and patients who initially received neoadjuvant chemotherapy and those whose adjuvant chemotherapy was not platinum-based were excluded from the analysis. Results: A total of 159 women were enrolled in the study, while data were analyzed for 116 patients. Their median age was 59 years (23-80 years) and did not have a significant influence on the treatment outcome. Clear-cell histological type of AOC was an important risk factor for a disease-free interval (DFI) (HR = 2.41, CI 95 % 0.9-5.9; p = 0.08) and overall survival (OS) (HR 4.045; 95.0% CI 1.5-10.6; p = 0.003). Post-operative residual tumour larger than 2 cm represented a statistically independent risk factor for poor OS. Residual tumour in the upper abdomen did not represent a statistically significant risk factor either for DFI (HR = 1.93; CI 95 % 0.9-4.06; p = 0.08) or for OS (HR = 1.47; 95.0 % CI 0.5-3.8; p = 0.491). Median follow up time was 29.5 months, median DFI 18 months (95 % CI 16-20) and median OS 32 months (95 % CI 22-42). 74 (63.8 %) patients died. Conclusion: Clear-cell histological type of AOC and residual tumour larger than 2 cm are the most important risk factors for early progress of the disease and poor OS. Hence improvement of surgical treatment is crucial for better treatment outcomes for patients with AOC. The latter can be achieved by an interdisciplinary surgical approach.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 50 条
  • [21] Optimal cytoreduction for advanced epithelial ovarian cancer: A commentary
    Eisenkop, Scott M.
    Spirtos, Nick M.
    Lin, Wei-Chien Michael
    GYNECOLOGIC ONCOLOGY, 2006, 103 (01) : 329 - 335
  • [22] Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment
    Fleury, A. C.
    Kushnir, C. L.
    Giuntoli, R. L., II
    Spirtos, N. M.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 (02) : 202 - 206
  • [23] "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer
    Zighelboim, Israel
    Kizer, Nora
    Taylor, Nicholas P.
    Case, Ashley S.
    Gao, Feng
    Thaker, Premal H.
    Rader, Janet S.
    Massad, L. Stewart
    Mutch, David G.
    Powell, Matthew A.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 370 - 373
  • [24] Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction
    McLean, Kate A.
    Shah, Chirag A.
    Thompson, Sara A.
    Gray, Heidi J.
    Swensen, Ron E.
    Goff, Barbara A.
    GYNECOLOGIC ONCOLOGY, 2010, 118 (01) : 43 - 46
  • [25] Optimal primary surgical treatment for advanced epithelial ovarian cancer
    Elattar, Ahmed
    Bryant, Andrew
    Winter-Roach, Brett A.
    Hatem, Mohamed
    Naik, Raj
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (08):
  • [26] Comparison of optimal cytoreduction rates in emergency versus non-emergency admissions for advanced ovarian cancer: A multi-institutional study
    Mangili, G.
    Scambia, G.
    Ottolina, J.
    Fanfani, F.
    Vigano, R.
    Costantini, B.
    Candiani, M.
    Fagotti, A.
    EJSO, 2013, 39 (08): : 906 - 911
  • [27] Prognostic factors in advanced ovarian cancer
    Cervantes, A
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997, 7 : 4 - 8
  • [28] Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer
    Jung, Dae Chul
    Kang, Sokbom
    Kim, Min Ju
    Park, Sang Yoon
    Kim, Hyun Beom
    EUROPEAN RADIOLOGY, 2010, 20 (01) : 100 - 107
  • [29] Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective study
    Testa, A. C.
    Ludovisi, M.
    Mascilini, F.
    Di Legge, A.
    Malaggese, M.
    Fagotti, A.
    Fanfani, F.
    Salerno, M. G.
    Ercoli, A.
    Scambia, G.
    Ferrandina, G.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2012, 39 (01) : 99 - 105
  • [30] Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer
    Salih Taşkın
    Mete Güngör
    Fırat Ortaç
    Derya Öztuna
    Archives of Gynecology and Obstetrics, 2013, 288 : 1399 - 1403